Cost-Effectiveness Analysis: Lymph Node Transfer vs Lymphovenous Bypass for Breast Cancer-Related Lymphedema

Effectiveness Analysis ◽

Breast Cancer Related Lymphedema ◽

Lymph Node Transfer

PCN122 COST-EFFECTIVENESS ANALYSIS OF TRASUTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR WOMEN WITH HER2+ ADJUVANT BREAST CANCER IN FRANCE

Value in Health ◽

10.1016/j.jval.2019.09.318 ◽

2019 ◽

Vol 22 ◽

pp. S459 ◽

Cited By ~ 1

Author(s):

A. Gherardi ◽

R. Sellami ◽

B. Tehard ◽

S. Roze

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Effectiveness Analysis ◽

Adjuvant Breast Cancer

58P Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.03.072 ◽

2021 ◽

Vol 32 ◽

pp. S45

Author(s):

X. Guan ◽

H-C. Li ◽

Q-J. Chen ◽

B. Hua ◽

J-J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Chinese Patients ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1909478 ◽

2021 ◽

pp. 1-10

Author(s):

Carlos Henrique Botelho ◽

Maria Del Pilar Estevez-Diz ◽

Alessandro Gonçalves Campolina

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

PCN69 Cost-Effectiveness Analysis of NOVEL Therapies for HER2+ Metastatic Breast Cancer: [FAM-] Trastuzumab Deruxtecan Versus Tucatinib Trastuzumab and Capecitabine Combination

Value in Health ◽

10.1016/j.jval.2020.08.206 ◽

2020 ◽

Vol 23 ◽

pp. S433-S434

Author(s):

G. Vondeling ◽

E. Palaka ◽

C. Livings ◽

J. Naik ◽

W. Sullivan

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Novel Therapies ◽

Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3107-3 ◽

2014 ◽

Vol 147 (2) ◽

pp. 443-443 ◽

Cited By ~ 1

Author(s):

Vakaramoko Diaby ◽

Georges Adunlin ◽

Simon B. Zeichner ◽

Kiran Avancha ◽

Gilberto Lopes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

A Cost-Effectiveness Analysis of Palbociclib and other Aromatase Inhibitors for Treatment of Advanced Breast Cancer

Value in Health ◽

10.1016/j.jval.2016.03.1589 ◽

2016 ◽

Vol 19 (3) ◽

pp. A150 ◽

Cited By ~ 6

Author(s):

K Bhattacharya ◽

Y Yang

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Aromatase Inhibitors ◽

Advanced Breast ◽

Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases

Journal of Clinical Oncology ◽

10.1200/jco.2017.77.0115 ◽

2018 ◽

Vol 36 (10) ◽

pp. 1051-1051 ◽

Cited By ~ 3

Author(s):

Lisa Kennedy ◽

Sumita Bhatta ◽

Guy Hechmati ◽

Jacqueline Buchanan

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Zoledronic Acid ◽

Skeletal Metastases ◽

Cancer screening cost-effectiveness analysis of the Chechen Republic population for erly detection of breast cancer and colorectal cancer

Profilakticheskaya meditsina ◽

10.17116/profmed20212403122 ◽

2021 ◽

Vol 24 (3) ◽

pp. 22

Author(s):

T.V. Gazieva ◽

I.A. Mikhailov ◽

P.G. Malkov ◽

E.A. Suleymanov ◽

G.A. Frank

Keyword(s):

Breast Cancer ◽

Colorectal Cancer ◽

Cost Effectiveness ◽

Cancer Screening ◽

Screening Cost ◽

CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

Value in Health ◽

10.1016/j.jval.2019.09.048 ◽

2019 ◽

Vol 22 ◽

pp. S405-S406

Author(s):

X. Guan ◽

H. Li ◽

Q. Chen ◽

C. Hao ◽

J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

High Risk ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Her2 Positive ◽

Risk Of Recurrence ◽

Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system

Journal of Medical Economics ◽

10.1080/13696998.2020.1821039 ◽

2020 ◽

Vol 23 (11) ◽

pp. 1340-1344

Author(s):

Rodrigo Shimabukuro Ho ◽

Mariana Mioti Sebastião ◽

João Paulo Venezian de Carvalho ◽

Tomás Neves ◽

Micha Nussbaum

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Healthcare System ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Private Healthcare ◽